Hormonal
HOMA-IR loses diagnostic accuracy for metabolic syndrome in non-diabetic women over 70 years of age, rendering it an unreliable screening tool for this specific subgroup.
If you are a non-diabetic woman over 70, a HOMA-IR test may not accurately reflect your metabolic risk. The study suggests this test becomes unreliable in this age group. Focus on direct measures of metabolic health: monitor blood pressure, lipid profiles, waist circumference, and blood glucose directly, as these are more robust indicators for your demographic.
For patients older than 70 years, the bootstrap confidence intervals for the AUC includes 0.5; thus there is no evidence suggesting that HOMA-IR can be used to classify non-diabetic older women with cardio metabolic risk.
Why this rating
Statistically significant finding in a large cohort, but limited to a specific demographic subgroup.
Source
Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study
Pilar Díz et al. · BMC Endocrine Disorders · 2013
DOI 10.1186/1472-6823-13-47
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →